

## REFERENCES

- Abdi, E., Latifi-Navid, S., Zahri, S., Kholghi-Oskoei, V., & Yazdanbod, A. (2021). Novel long intergenic non-coding RNA—AC064834.1—misregulation in gastric cancer. *Gene Reports*, 24, 101256. <https://doi.org/10.1016/j.genrep.2021.101256>
- Bhat, S. A., Ahmad, S. M., Mumtaz, P. T., Malik, A. A., Dar, M. A., Urwat, U., Shah, R. A., & Ganai, N. A. (2016). Long non-coding RNAs: Mechanism of action and functional utility. *Non-Coding RNA Research*, 1(1), 43–50. <https://doi.org/10.1016/j.ncrna.2016.11.002>
- Brawley, O. W. (2012). Trends in prostate cancer in the United States. *JNCI Monographs*, 2012(45), 152–156. <https://doi.org/10.1093/jncimonographs/lgs035>
- Bussemakers, M. J., van Bokhoven, A., Verhaegh, G. W., Smit, F. P., Karthaus, H. F., Schalken, J. A., Debruyne, F. M., Ru, N., & Isaacs, W. B. (1999). DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. *Cancer research*, 59(23), 5975–5979.
- Chen, W., Wang, F., Zhang, J., Li, C., & Hong, L. (2022). LINC01087 indicates a poor prognosis of glioma patients with preoperative MRI. *Functional & integrative genomics*, 22(1), 55–64. <https://doi.org/10.1007/s10142-021-00812-w>
- Chiu, H. S., Somvanshi, S., Patel, E., Chen, T. W., Singh, V. P., Zorman, B., Patil, S. L., Pan, Y., Chatterjee, S. S., Sood, A. K., Gunaratne, P. H., Sumazin, P., Caesar-Johnson, S. J., Demchok, J. A., Felau, I., Kasapi, M., Ferguson, M. L., Hutter, C. M., Sofia, H. J., ... Mariamidze, A. (2018). Pan-Cancer analysis of lncRNA Regulation supports their targeting of cancer genes in each tumor context. *Cell Reports*, 23(1). <https://doi.org/10.1016/j.celrep.2018.03.064>
- Choi, S.-W., Kim, H.-W., & Nam, J.-W. (2019). The small peptide world in long noncoding RNAs. *Briefings in Bioinformatics*, 20(5), 1853–1864. <https://doi.org/10.1093/bib/bby055>
- Chu, C., Zhang, Q. C., Rocha, S. T., Flynn, R. A., Bharadwaj, M., Calabrese, J. M., Magnuson, T., Heard, E., & Chang, H. Y. (2015). Systematic discovery of Xist RNA binding proteins. *Cell*, 161(2), 404–416. <https://doi.org/10.1016/j.cell.2015.03.025>
- Cui, Y., Cui, Y., Gu, R., Liu, Y., Wang, X., Bi, L., Zhang, S., Fan, W., Tian, F., Zhan, Y., Zhang, N., Xing, Y., & Cai, L. (2021). Identification of Differentially Expressed and Prognostic lncRNAs for the Construction of ceRNA Networks in Lung Adenocarcinoma. *Journal of oncology*, 2021, 2659550. <https://doi.org/10.1155/2021/2659550>
- Da Rocha, S. T., Boeva, V., Escamilla-Del-Arenal, M., Ancelin, K., Granier, C., Matias, N. R., Sanulli, S., Chow, J., Schulz, E., Picard, C., Kaneko, S., Helin, K., Reinberg, D., Stewart, A. F., Wutz, A., Margueron, R., & Heard, E. (2014). Jarid2 is implicated in the initial Xist-induced targeting of PRC2 to the inactive X chromosome. *Molecular Cell*, 53(2), 301–316. <https://doi.org/10.1016/j.molcel.2014.01.002>
- da Silveira, W., Renaud, L., Simpson, J., Glen, W., Hazard, E., Chung, D., & Hardiman, G. (2018). MiRmapper: A tool for interpretation of MIRNA–mRNA interaction networks. *Genes*, 9(9), 458. <https://doi.org/10.3390/genes9090458>
- Dai, G., Huang, C., Yang, J., Jin, L., Fu, K., Yuan, F., Zhu, J., & Xue, B. (2020). lncRNA SNHG3 promotes bladder

- cancer proliferation and metastasis through Mir-515-5p/Gins2 Axis. *Journal of Cellular and Molecular Medicine*, 24(16), 9231–9243. <https://doi.org/10.1111/jcmm.15564>
- DeSantis, C. E., Miller, K. D., Goding Sauer, A., Jemal, A., & Siegel, R. L. (2019). Cancer statistics for African Americans, 2019. *CA: A Cancer Journal for Clinicians*, 69(3), 211–233. <https://doi.org/10.3322/caac.21555>
- Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2012). Star: Ultrafast universal RNA-seq aligner. *Bioinformatics*, 29(1), 15–21. <https://doi.org/10.1093/bioinformatics/bts635>
- Etzioni, R., Penson, D. F., Legler, J. M., di Tommaso, D., Boer, R., Gann, P. H., & Feuer, E. J. (2002). Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. *Journal of the National Cancer Institute*, 94(13), 981–990. <https://doi.org/10.1093/jnci/94.13.981>
- Fan, Y., Shen, B., Tan, M., Mu, X., Qin, Y., Zhang, F., & Liu, Y. (2014). TGF- $\beta$ -induced upregulation of malat1 promotes bladder cancer metastasis by associating with *suz12*. *Clinical Cancer Research*, 20(6), 1531–1541. <https://doi.org/10.1158/1078-0432.ccr-13-1455>
- Feibus, A. H., Sartor, O., Moparty, K., Chagin, K., Kattan, M. W., Ledet, E., Levy, J., Lee, B., Thomas, R., & Silberstein, J. L. (2016). Clinical use of PCA3 and TMPRSS2:erg urinary biomarkers in African-American men undergoing prostate biopsy. *Journal of Urology*, 196(4), 1053–1060. <https://doi.org/10.1016/j.juro.2016.04.075>
- Frey, L. (2018). Artificial Intelligence and integrated genotype–phenotype identification. *Genes*, 10(1), 18. <https://doi.org/10.3390/genes10010018>
- García-Perdomo, H. A., Chaves, M. J., Osorio, J. C., & Sanchez, A. (2018). Association between TMPRSS2:ERG fusion gene and the prostate cancer: systematic review and meta-analysis. *Central European Journal of Urology*, 71(4), 410–419. <https://doi.org/10.5173/cej.2018.1752>
- Gao, P., Sun, D., Guo, H., Wu, Z., & Chen, J. (2020). LncRNA CCAT2 promotes proliferation and suppresses apoptosis of colorectal cancer cells. *Journal of B.U.ON. : official journal of the Balkan Union of Oncology*, 25(4), 1840–1846.
- Gobernado, I., Sanchez-Herranz, A., & Jimenez-Escrig, A. (2014). Next-generation sequencing. *Fundamentals of Advanced Omics Technologies: From Genes to Metabolites*, 47–79. <https://doi.org/10.1016/b978-0-444-62651-6.00003-9>
- Gu, S., Zhang, G., Si, Q., Dai, J., Song, Z., & Wang, Y. (2021). Web tools to perform long non-coding RNAs analysis in oncology research. *Database : The Journal of Biological Databases and Curation*, baab047. <https://doi.org/10.1093/database/baab047>
- Hardiman, G., Savage, S. J., Hazard, E. S., Wilson, R. C., Courtney, S. M., Smith, M. T., Hollis, B. W., Halbert, C. H., & Gattoni-Celli, S. (2016). Systems analysis of the prostate transcriptome in African–American men compared with European–American men. *Pharmacogenomics*, 17(10), 1129–1143. <https://doi.org/10.2217/pgs-2016-0025>
- Hardiman, G., Savage, S. J., Hazard, E. S., da Silveira, W. A., Morgan, R., Harris, A., Jefferson, M. S., Wilson, R. C., Caulder, S., Ambrose, L., Frey, L., Wolf, B., Gattoni-Celli, S., & Hughes Halbert, C. (2021). A systems approach to interrogate gene expression patterns in African American men presenting with clinically localized prostate

- cancer. *Cancers*, 13(20), 5143. <https://doi.org/10.3390/cancers13205143>
- Hu, X., Wang, Q., Tang, M., Barthel, F., Amin, S., Yoshihara, K., Lang, F. M., Martinez-Ledesma, E., Lee, S. H., Zheng, S., & Verhaak, R. G. (2017). Tumor fusions: An integrative resource for cancer-associated transcript fusions. *Nucleic Acids Research*, 46(D1). <https://doi.org/10.1093/nar/gkx1018>
- Jiang, M. C., Ni, J. J., Cui, W. Y., Wang, B. Y., & Zhuo, W. (2019). Emerging roles of lncRNA in cancer and therapeutic opportunities. *American journal of cancer research*, 9(7), 1354–1366.
- Koutrouli, M., Karatzas, E., Paez-Espino, D., & Pavlopoulos, G. A. (2020). A guide to conquer the Biological Network Era using graph theory. *Frontiers in Bioengineering and Biotechnology*, 8. <https://doi.org/10.3389/fbioe.2020.00034>
- Lågstad, S., Zhao, S., Hoff, A. M., Johannessen, B., Lingjærde, O. C., & Skotheim, R. I. (2017). chimeraviz: A tool for visualizing chimeric RNA. *Bioinformatics*, 33(18), 2954–2956. <https://doi.org/10.1093/bioinformatics/btx329>
- Laner, T., Schulz, W. A., Engers, R., Müller, M., & Florl, A. R. (2005). Hypomethylation of the xist gene promoter in prostate cancer. *Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics*, 15(5), 257–264. <https://doi.org/10.3727/096504005776404607>
- Lee, D. J., Mallin, K., Graves, A. J., Chang, S. S., Penson, D. F., Resnick, M. J., & Barocas, D. A. (2017). Recent Changes in Prostate Cancer Screening Practices and Epidemiology. *The Journal of Urology*, 198(6), 1230–1240. <https://doi.org/10.1016/j.juro.2017.05.074>
- Leslie, S. W., Soon-Sutton, T. L., R I, A., Sajjad, H., & Siref, L. E. (2022). Prostate Cancer. In: *StatPearls. Treasure Island (FL): StatPearls Publishing*. Retrieved March 15, 2023, from: <https://www.ncbi.nlm.nih.gov/books/NBK470550/>
- Li, D. S., Ainiwaer, J. L., Sheyhiding, I., Zhang, Z., & Zhang, L. W. (2016). Identification of key long non-coding RNAs as competing endogenous RNAs for miRNA-mRNA in lung adenocarcinoma. *European review for medical and pharmacological sciences*, 20(11), 2285–2295.
- Li, H., Gao, J., Liu, L., & Zhang, S. (2022). linc00958: A promising long non-coding RNA related to cancer. *Biomedicine & Pharmacotherapy*, 151, 113087. <https://doi.org/10.1016/j.biopha.2022.113087>
- Liu, Y., Morley, M., Brandimarto, J., Hannenhalli, S., Hu, Y., Ashley, E. A., Tang, W. H. W., Moravec, C. S., Margulies, K. B., Cappola, T. P., & Li, M. (2015). RNA-seq identifies novel myocardial gene expression signatures of heart failure. *Genomics*, 105(2), 83–89. <https://doi.org/10.1016/j.ygeno.2014.12.002>
- Love, M. I., Huber, W., & Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biology*, 15(12). <https://doi.org/10.1186/s13059-014-0550-8>
- Ma, L., Cao, J., Liu, L., Du, Q., Li, Z., Zou, D., Bajic, V. B., & Zhang, Z. (2018). LncBook: A curated knowledgebase of human long non-coding RNAs. *Nucleic Acids Research*, 47(D1). <https://doi.org/10.1093/nar/gky960>
- Ma, X., & Yu, H. (2006). Global burden of cancer. *The Yale journal of biology and medicine*, 79(3-4), 85–94.
- Mendell, J. T. (2016). Targeting a long noncoding RNA in breast cancer. *New England Journal of Medicine*, 374(23), 2287–2289. <https://doi.org/10.1056/nejmcibr1603785>
- Mirzaei, S., Paskeh, M. D., Okina, E., Gholami, M. H., Hushmandi, K., Hashemi, M., Kalu, A., Zarrabi, A., Nabavi, N., Rabiee, N., Sharifi, E., Karimi-Maleh, H., Ashrafizadeh, M., Kumar, A. P., & Wang, Y. (2022). Molecular

- landscape of lncRNAs in prostate cancer: A focus on pathways and therapeutic targets for intervention. *Journal of Experimental & Clinical Cancer Research*, 41(1). <https://doi.org/10.1186/s13046-022-02406-1>
- Misawa, A., Takayama, K., & Inoue, S. (2017). Long non-coding RNAs and prostate cancer. *Cancer Science*, 108(11), 2107–2114. <https://doi.org/10.1111/cas.13352>
- Mitobe, Y., Takayama, K.-ichi, Horie-Inoue, K., & Inoue, S. (2018). Prostate cancer-associated lncRNAs. *Cancer Letters*, 418, 159–166. <https://doi.org/10.1016/j.canlet.2018.01.012>
- Morgan, R., da Silveira, W. A., Kelly, R. C., Overton, I., Allott, E. H., & Hardiman, G. (2021). Long non-coding RNAs and their potential impact on diagnosis, prognosis, and therapy in prostate cancer: racial, ethnic, and geographical considerations. *Expert Review of Molecular Diagnostics*, 21(12), 1257–1271. <https://doi.org/10.1080/14737159.2021.1996227>
- Moschny, N., Zindler, T., Jahn, K., Dorda, M., Davenport, C. F., Wiehlmann, L., Maier, H. B., Eberle, F., Bleich, S., Neyazi, A., & Frieling, H. (2020). Novel candidate genes for ECT response prediction—a pilot study analyzing the DNA methylome of depressed patients receiving electroconvulsive therapy. *Clinical Epigenetics*, 12(1), 114. <https://doi.org/10.1186/s13148-020-00891-9>
- Mouraviev, V., Lee, B., Patel, V., Albala, D., Johansen, T. E., Partin, A., Ross, A., & Perera, R. J. (2015). Clinical prospects of long noncoding RNAs as novel biomarkers and therapeutic targets in prostate cancer. *Prostate Cancer and Prostatic Diseases*, 19(1), 14–20. <https://doi.org/10.1038/pcan.2015.48>
- National Cancer Institute. (2020). Cancer of the prostate - cancer stat facts. SEER. Retrieved March 21, 2023, from <https://seer.cancer.gov/statfacts/html/prost.html>
- Parolia, A., Crea, F., Xue, H., Wang, Y., Mo, F., Ramnarine, V. R., Liu, H. H., Lin, D., Saidy, N. R., Clermont, P.-L., Cheng, H., Collins, C., Wang, Y., & Helgason, C. D. (2015). The long non-coding RNA PCGEM1 is regulated by androgen receptor activity in vivo. *Molecular Cancer*, 14(1). <https://doi.org/10.1186/s12943-015-0314-4>
- Petrovics, G., Zhang, W., Makarem, M., Street, J. P., Connelly, R., Sun, L., Sesterhenn, I. A., Srikantan, V., Moul, J. W., & Srivastava, S. (2004). Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. *Oncogene*, 23(2), 605–611. <https://doi.org/10.1038/sj.onc.1207069>
- Ponting, C. P., Oliver, P. L., & Reik, W. (2009). Evolution and functions of long noncoding RNAs. *Cell*, 136(4), 629–641. <https://doi.org/10.1016/j.cell.2009.02.006>
- Prensner, J. R., Iyer, M. K., Balbin, O. A., Dhanasekaran, S. M., Cao, Q., Brenner, J. C., Laxman, B., Asangani, I. A., Grasso, C. S., Kominsky, H. D., Cao, X., Jing, X., Wang, X., Siddiqui, J., Wei, J. T., Robinson, D., Iyer, H. K., Palanisamy, N., Maher, C. A., & Chinnaiyan, A. M. (2011). Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. *Nature Biotechnology*, 29(8), 742–749. <https://doi.org/10.1038/nbt.1914>
- Quinn, J. J., & Chang, H. Y. (2016). Unique features of long non-coding RNA biogenesis and function. *Nature reviews. Genetics*, 17(1), 47–62. <https://doi.org/10.1038/nrg.2015.10>
- Rebbeck, T. R., Devesa, S. S., Chang, B.-L., Bunker, C. H., Cheng, I., Cooney, K., Eeles, R., Fernandez, P., Giri, V. N., Gueye, S. M., Haiman, C. A., Henderson, B. E., Heyns, C. F., Hu, J. J., Ingles, S. A., Isaacs, W., Jalloh, M., John,

- E. M., Kibel, A. S., ... Zeigler-Johnson, C. M. (2013). Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of African descent. *Prostate Cancer*, 2013, 1–12. <https://doi.org/10.1155/2013/560857>
- Richards, Z., Batai, K., Farhat, R., Shah, E., Makowski, A., Gann, P. H., Kittles, R., & Nonn, L. (2017). Prostatic compensation of the vitamin D axis in African American men. *JCI Insight*, 2(2). <https://doi.org/10.1172/jci.insight.91054>
- Roberts, M. J., Teloken, P., Chambers, S. K., Williams, S. G., Yaxley, J., Samaratunga, H., Frydenberg, M., & Gardiner, R. A. (2018). *Prostate Cancer Detection*. In K. R. Feingold (Eds.) et. al., Endotext. MDText.com, Inc.
- Salviano-Silva, A., Lobo-Alves, S. C., Almeida, R. C., Malheiros, D., & Petzl-Erler, M. L. (2018). Besides Pathology: Long Non-Coding RNA in Cell and Tissue Homeostasis. *Non-coding RNA*, 4(1), 3. <https://doi.org/10.3390/ncrna4010003>
- Scharff, D. P., Mathews, K. J., Jackson, P., Hoffsuemmer, J., Martin, E., & Edwards, D. (2010). More than Tuskegee: Understanding mistrust about research participation. *Journal of Health Care for the Poor and Underserved*, 21(3), 879–897. <https://doi.org/10.1353/hpu.0.0323>
- Schwartz, G. G. (2005). Vitamin D in health and disease: Vitamin D and the epidemiology of prostate cancer. *Seminars in Dialysis*, 18(4), 276–289. <https://doi.org/10.1111/j.1525-139x.2005.18403.x>
- Shi, Q., Li, Y., Li, S., Jin, L., Lai, H., Wu, Y., Cai, Z., Zhu, M., Li, Q., Li, Y., Wang, J., Liu, Y., Wu, Z., Song, E., & Liu, Q. (2020). LncRNA DILA1 inhibits cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer. *Nature Communications*, 11(1). <https://doi.org/10.1038/s41467-020-19349-w>
- She, J. K., Fu, D. N., Zhen, D., Gong, G. H., & Zhang, B. (2020). LINC01087 is Highly Expressed in Breast Cancer and Regulates the Malignant Behavior of Cancer Cells Through miR-335-5p/Rock1. *OncoTargets and therapy*, 13, 9771–9783. <https://doi.org/10.2147/OTT.S255994>
- Siegel, R. L., Miller, K. D., & Jemal, A. (2020). Cancer statistics, 2020. *CA: A Cancer Journal for Clinicians*, 70(1), 7–30. <https://doi.org/10.3322/caac.21590>.
- Sullivan, G. M., & Feinn, R. (2012). Using effect size—or why the p value is not enough. *Journal of Graduate Medical Education*, 4(3), 279–282. <https://doi.org/10.4300/jgme-d-12-00156.1>
- Smith, C. J., Ambs, S., & Landgren, O. (2018). Biological determinants of health disparities in multiple myeloma. *Blood Cancer Journal*, 8(9). <https://doi.org/10.1038/s41408-018-0118-z>
- The FANTOM Consortium and the RIKEN Genome Exploration Research Group Phase I & II Team\*. (2002). Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. *Nature*, 420(6915), 563–573. <https://doi.org/10.1038/nature01266>
- The International Agency for Research on Cancer (IARC). (2020). Global cancer observatory. Global Cancer Observatory. Retrieved April 6, 2023, from <https://gco.iarc.fr/>
- Tonmoy, M. I. Q., Fariha, A., Hami, I., Kar, K., Reza, H. A., Bahadur, N. M., & Hossain, M. S. (2022). Computational epigenetic landscape analysis reveals association of CACNA1G-AS1, F11-AS1, NNT-AS1, and MSC-AS1 lncRNAs in prostate cancer progression through aberrant methylation. *Scientific reports*, 12(1), 10260. <https://doi.org/10.1038/s41598-022-13381-0>
- U.S. National Library of Medicine. (2022). Human genome overview - genome reference consortium. National

- Center for Biotechnology Information. Retrieved April 21, 2023, from <https://www.ncbi.nlm.nih.gov/grc/human>
- Torres-García, W., Zheng, S., Sivachenko, A., Vegesna, R., Wang, Q., Yao, R., Berger, M. F., Weinstein, J. N., Getz, G., & Verhaak, R. G. W. (2014). Prada: Pipeline for RNA sequencing data analysis. *Bioinformatics*, 30(15), 2224–2226. <https://doi.org/10.1093/bioinformatics/btu169>
- Wallace, T. A., Prueitt, R. L., Yi, M., Howe, T. M., Gillespie, J. W., Yfantis, H. G., Stephens, R. M., Caporaso, N. E., Loffredo, C. A., & Ambros, S. (2008). Tumor immunobiological differences in prostate cancer between African-American and European-American men. *Cancer Research*, 68(3), 927–936. <https://doi.org/10.1158/0008-5472.can-07-2608>
- Walsh, A. L., Tuzova, A. V., Bolton, E. M., Lynch, T. H., & Perry, A. S. (2014). Long noncoding RNAs and prostate carcinogenesis: The missing 'linc'? *Trends in Molecular Medicine*, 20(8), 428–436. <https://doi.org/10.1016/j.molmed.2014.03.005>
- Wang, F., Zu, Y., Huang, W., Chen, H., Xie, H., & Yang, Y. (2018). LncRNA CALML3-AS1 promotes tumorigenesis of bladder cancer via regulating ZBTB2 by suppression of microRNA-4316. *Biochemical and biophysical research communications*, 504(1), 171–176. <https://doi.org/10.1016/j.bbrc.2018.08.150>
- Wang, K. C., & Chang, H. Y. (2011). Molecular mechanisms of long noncoding RNAs. *Molecular Cell*, 43(6), 904–914. <https://doi.org/10.1016/j.molcel.2011.08.018>
- Wilhelm, B. T., & Landry, J. R. (2009). RNA-Seq-quantitative measurement of expression through massively parallel RNA-sequencing. *Methods (San Diego, Calif.)*, 48(3), 249–257. <https://doi.org/10.1016/j.ymeth.2009.03.016>
- Wu, T., & Du, Y. (2017). LncRNAs: From basic research to medical application. *International Journal of Biological Sciences*, 13(3), 295–307. <https://doi.org/10.7150/ijbs.16968>
- Xiong, T., Li, J., Chen, F., & Zhang, F. (2019). PCAT-1: A novel oncogenic long non-coding RNA in human cancers. *International Journal of Biological Sciences*, 15(4), 847–856. <https://doi.org/10.7150/ijbs.30970>
- Zhang, M., Wang, Q., Ke, Z., Liu, Y., Guo, H., Fang, S., & Lu, K. (2021). LINC01001 Promotes Progression of Crizotinib-Resistant NSCLC by Modulating IGF2BP2/MYC Axis. *Frontiers in pharmacology*, 12, 759267. <https://doi.org/10.3389/fphar.2021.759267>
- Zhang, Y., Li, Z., Chen, M., Chen, H., Zhong, Q., Liang, L., & Li, B. (2020). LncRNA TCL6 correlates with immune cell infiltration and indicates worse survival in breast cancer. *Breast Cancer*, 27(4), 573–585. <https://doi.org/10.1007/s12282-020-01048-5>
- Zhao, S., Fung-Leung, W.-P., Bittner, A., Ngo, K., & Liu, X. (2014). Comparison of RNA-seq and microarray in transcriptome profiling of activated T cells. *PLoS ONE*, 9(1). <https://doi.org/10.1371/journal.pone.0078644>
- Zuo, X., Chen, Z., Gao, W., Zhang, Y., Wang, J., Wang, J., Cao, M., Cai, J., Wu, J., & Wang, X. (2020). M6A-mediated upregulation of LINC00958 increases lipogenesis and acts as a nanotherapeutic target in hepatocellular carcinoma. *Journal of Hematology & Oncology*, 13(1). <https://doi.org/10.1186/s13045-019-0839-x>